Real-World Impact of Survival by Period of Diagnosis in Epithelial Ovarian Cancer Between 1990 and 2014

Allemani, 2018, Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries, Lancet., 391, 1023, 10.1016/S0140-6736(17)33326-3

Torre, 2018, Ovarian cancer statistics, 2018, CA Cancer J Clin., 68, 284, 10.3322/caac.21456

Bast, 2005, New tumor markers: CA125 and beyond, Int J Gynecol Cancer., 15, 2741, 10.1111/j.1525-1438.2005.00441.x

Badgwell, 2007, Early detection of ovarian cancer, Dis Markers., 23, 397, 10.1155/2007/309382

Rosenthal, 2006, Screening for ovarian cancer, Clin Obstet Gynecol., 49, 433, 10.1097/00003081-200609000-00004

Buys, 2011, Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial, JAMA., 305, 2295, 10.1001/jama.2011.766

Barnholtz-Sloan, 2003, Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades, Am J Obstet Gynecol., 189, 1120, 10.1067/S0002-9378(03)00579-9

2018, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) -Ovarian Cancer Version 2

Suh, 2018, Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement, J Gynecol Oncol., 29, e56, 10.3802/jgo.2018.29.e56

Akhtar-Danesh, 2011, Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992–2005: a population-based study, Gynecol Oncol., 123, 192, 10.1016/j.ygyno.2011.07.098

Trétarre, 2015, Ovarian cancer in France: trends in incidence, mortality and survival, 1980–2012, Gynecol Oncol., 139, 324, 10.1016/j.ygyno.2015.09.013

Chan, 2008, The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?, Br J Cancer., 98, 1191, 10.1038/sj.bjc.6604299

Timmermans, 2018, No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands, Eur J Cancer., 88, 31, 10.1016/j.ejca.2017.10.030

Warren, 2017, Trends in the receipt of guideline care and survival for women with ovarian cancer: a population-based study, Gynecol Oncol., 145, 486, 10.1016/j.ygyno.2017.03.016

Tan, 2009, Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a Gynecologic Oncology Group member treatment center: 1979–2001, Gynecol Oncol., 114, 346, 10.1016/j.ygyno.2009.03.033

Chen, 2018, Epithelial ovarian cancer mortality among Hispanic women: sub-ethnic disparities and survival trend across time: an analysis of SEER 1992–2013, Cancer Epidemiol., 52, 134, 10.1016/j.canep.2017.12.003

Young, 2001, SEER Summary Staging Manual - 2000: Codes and Coding Instructions

Kurman, 2014, WHO Classification of Tumours of Female Reproductive Organs

Chen, 2003, Pathology and classification of ovarian tumors, Cancer., 97, 2631, 10.1002/cncr.11345

Menon, 2014, Ovarian cancer screening–current status, future directions, Gynecol Oncol., 132, 490, 10.1016/j.ygyno.2013.11.030

McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med., 334, 1, 10.1056/NEJM199601043340101

Chi, 2001, Identification of prognostic factors in advanced epithelial ovarian carcinoma, Gynecol Oncol., 82, 532, 10.1006/gyno.2001.6328

van Altena, 2012, Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands, Gynecol Oncol., 125, 649, 10.1016/j.ygyno.2012.02.033

Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, J Clin Oncol., 20, 1248, 10.1200/JCO.2002.20.5.1248

Averette, 1995, The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society, Cancer., 76, 1096, 10.1002/1097-0142(19950915)76:6<1096::AID-CNCR2820760626>3.0.CO;2-4

Broekman, 2018, Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores, Cancer Treat Rev., 69, 233, 10.1016/j.ctrv.2018.06.008

Mirza, 2016, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, N Engl J Med., 375, 2154, 10.1056/NEJMoa1611310

Bellone, 2018, Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement, Clin Cancer Res., 24, 3282, 10.1158/1078-0432.CCR-17-1805

Vernooij, 2007, The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review, Gynecol Oncol., 105, 801, 10.1016/j.ygyno.2007.02.030

Noone, 2016, Comparison of SEER treatment data with medicare claims, Med Care., 54, e55, 10.1097/MLR.0000000000000073